2 March 2016 - Consider this, you're a multinational company peddling a relatively new melanoma cancer drug that's been effective for one out of three users. You obviously want a foothold in a country that has the highest melanoma rates in the world but the Government won't publicly fund your drug because it's not satisfied that it's the most effective on the market.

For more details, go to: http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=11598544